Synergistic and selective cancer cell killing mediated by the oncolytic adenoviral mutant adδδ and dietary phytochemicals in prostate cancer models

Human Gene Therapy

Volumn 23, Issue 9, 2012, Pages 1003-1015

  Adam, Virginie ^a,c   Ekblad, Maria ^a   Sweeney, Katrina ^a   Müller, Heike ^a   Busch, Kristina Hammarén ^b   Johnsen, Camilla Tørnqvist ^b   Kang, Na Ra ^a   Lemoine, Nick R ^a   Halldén, Gunnel ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ROYAL VETERINARY COLLEGE   (United Kingdom)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CASPASE 3; CURCUMIN; E1A PROTEIN; EPIGALLOCATECHIN GALLATE; EQUOL; GENISTEIN; MESSENGER RNA; ONCOLYTIC ADENOVIRUS; RESVERATROL;

ADENOVIRUS 5; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BRONCHUS; CANCER CELL CULTURE; CANCER INHIBITION; CELL KILLING; CELL VIABILITY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; EMBRYO; ENZYME ACTIVATION; EPITHELIUM CELL; FEASIBILITY STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PHYTOCHEMISTRY; PROSTATE CANCER; STATISTICAL SIGNIFICANCE; TUMOR XENOGRAFT; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; DIETARY SUPPLEMENTS; EQUOL; HUMANS; MALE; MICE; MICE, NUDE; MUTATION; NEOPLASM TRANSPLANTATION; ONCOLYTIC VIRUSES; PHYTOESTROGENS; PROSTATIC NEOPLASMS; STILBENES; TRANSPLANTATION, HETEROLOGOUS;

EID: 84866339835     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2012.046     Document Type: Article

References (46)

1. Abou El Hassan, M.A., van der Meulen-Muileman, I., Abbas, S., and Kruyt, F.A. (2004). Conditionally replicating adenoviruses kill tumor cells via a basic apoptotic machinery-independent mechanism that resembles necrosis-like programmed cell death. J. Virol. 78, 12243-12251. (Pubitemid 39458744)
2. Akaza, H., Miyanaga, N., Takashima, N., et al. (2004). Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents. Jpn. J. Clin. Oncol. 34, 86-89. (Pubitemid 43115325)
3. Anders, M., Christian, C., McMahon, M., et al. (2003). Inhibition of the Raf/MEK/ERK pathway up-regulates expression of the coxsackievirus and adenovirus receptor in cancer cells. Cancer Res. 63, 2088-2095. (Pubitemid 36538611)
4. Arico, S., Petiot, A., Bauvy, C., et al. (2001). The tumor suppressor PTEN positively regulates macroautophagy by inhibiting the phosphatidylinositol 3-kinase/protein kinase B pathway. J. Biol. Chem. 276, 35243-35246.
5. Bewley, M.C., Springer, K., Zhang, Y.B., et al. (1999). Structural analysis of the mechanism of adenovirus binding to its human cellular receptor, CAR. Science 286, 1579-1583.
6. Cheong, S.C., Wang, Y., Meng, J.H., et al. (2008). E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models. Cancer Gene Ther. 15, 40-50. (Pubitemid 350261299)
7. Cherubini, G., Petouchoff, T., Grossi, M., et al. (2006). E1B55K-deleted adenovirus (ONYX-015) overrides G1/S and G2/M checkpoints and causes mitotic catastrophe and endoreduplication in p53-proficient normal cells. Cell Cycle 5, 2244-2252. (Pubitemid 44546561)
8. Chou, T.C. (2006). Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621-681.
9. de la Lastra, C.A., and Villegas, I. (2005). Resveratrol as an antiinflammatory and anti-aging agent: mechanisms and clinical implications. Mol. Nutr. Food Res. 49, 405-430. (Pubitemid 40780389)
10. de Souza, P.L., Russell, P.J., Kearsley, J.H., and Howes, L.G. (2010). Clinical pharmacology of isoflavones and its relevance for potential prevention of prostate cancer. Nutr. Rev. 68, 542-555.
11. Dilley, J., Reddy, S., Ko, D., et al. (2005). Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity. Cancer Gene Ther. 12, 715-722. (Pubitemid 41045570)
12. Ekblad, M., and Hallden, G. (2010). Adenovirus-based therapy for prostate cancer. Curr. Opin. Mol. Ther. 12, 421-431.
13. Fimia, G.M., and Piacentini, M. (2010). Regulation of autophagy in mammals and its interplay with apoptosis. Cell Mol. Life Sci. 67, 1581-1588.
14. Freytag, S.O., Stricker, H., Peabody, J., et al. (2007). Five-year follow-up of trial of replication-competent adenovirusmediated suicide gene therapy for treatment of prostate cancer. Mol. Ther. 15, 636-642.
15. Frisch, S.M., and Mymryk, J.S. (2002). Adenovirus-5 E1A: paradox and paradigm. Nat. Rev. Mol. Cell Biol. 3, 441-452. (Pubitemid 34685701)
16. Gao, S., Liu, G.Z., and Wang, Z. (2004). Modulation of androgen receptor-dependent transcription by resveratrol and genistein in prostate cancer cells. Prostate 59, 214-225. (Pubitemid 38481232)
17. Garber, K. (2006). China approves world's first oncolytic virus therapy for cancer treatment. J. Natl. Cancer Inst. 98, 298-300.
18. Goel, A., and Aggarwal, B.B. (2010). Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr. Cancer 62, 919-930.
19. Hedlund, T.E., Johannes, W.U., and Miller, G.J. (2003). Soy isoflavonoid equol modulates the growth of benign and malignant prostatic epithelial cells in vitro. Prostate 54, 68-78. (Pubitemid 36043838)
20. Hemminki, A., Kanerva, A., Liu, B., et al. (2003). Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression. Cancer Res. 63, 847-853. (Pubitemid 36231986)
21. Ito, H., Aoki, H., Kuhnel, F., et al. (2006). Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus. J. Natl. Cancer Inst. 98, 625-636. (Pubitemid 43904846)
22. Jang, M., Cai, L., Udeani, G.O., et al. (1997). Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275, 218-220. (Pubitemid 127696281)
23. Jemal, A., Bray, F., Center, M.M., et al. (2011). Global cancer statistics. CA Cancer J. Clin. 61, 69-90.
24. Jiang, H., White, E.J., Rios-Vicil, C.I., et al. (2011). Human adenovirus type 5 induces cell lysis through autophagy and autophagy-triggered caspase activity. J. Virol. 85, 4720-4729.
25. Kwan, W., Duncan, G., Van Patten, C., et al. (2010). A phase II trial of a soy beverage for subjects without clinical disease with rising prostate-specific antigen after radical radiation for prostate cancer. Nutr. Cancer 62, 198-207.
26. Leitner, S., Sweeney, K., Oberg, D., et al. (2009). Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo. Clin. Cancer Res. 15, 1730-1740.
27. Li, E., Stupack, D., Klemke, R., et al. (1998). Adenovirus endocytosis via alpha(v) integrins requires phosphoinositide-3-OH kinase. J. Virol. 72, 2055-2061. (Pubitemid 28100760)
28. Liao, Y., Zou, Y.Y., Xia, W.Y., and Hung, M.C. (2004). Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a nonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer. Cancer Gene Ther. 11, 594-602. (Pubitemid 39195409)
29. Libertini, S., Abagnale, A., Passaro, C., et al. (2011). AZD1152 negatively affects the growth of anaplastic thyroid carcinoma cells and enhances the effects of oncolytic virus dl922-947. Endocr. Relat. Cancer 18, 129-141.
30. Liu, T.C., Galanis, E., and Kirn, D. (2007). Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat. Clin. Pract. Oncol. 4, 101-117.
31. Ö berg, D., Yanover, E., Sweeney, K., et al. (2010). Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers. Clin. Cancer Res. 16, 541-553.
32. Ogier-Denis, E., Pattingre, S., El Benna, J., and Codogno, P. (2000). Erk1/2-dependent phosphorylation of Galphainteracting protein stimulates its GTPase accelerating activity and autophagy in human colon cancer cells. J. Biol. Chem. 275, 39090-39095. (Pubitemid 32058923)
33. O'Shea, C.C., Johnson, L., Bagus, B., et al. (2004). Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 6, 611-623. (Pubitemid 40017704)
34. O'Shea, C.C., Choi, S., McCormick, F., and Stokoe, D. (2005). Adenovirus overrides cellular checkpoints for protein translation. Cell Cycle 4, 883-888. (Pubitemid 41359751)
35. Parato, K.A., Senger, D., Forsyth, P.A., and Bell, J.C. (2005). Recent progress in the battle between oncolytic viruses and tumours. Nat. Rev. Cancer 5, 965-976. (Pubitemid 41766784)
36. Radhakrishnan, S., Miranda, E., Ekblad, M., et al. (2010). Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts. Hum. Gene Ther. 21, 1311-1325.
37. Raki, M., Kanerva, A., Ristimaki, A., et al. (2005). Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer. Gene Ther. 12, 1198-1205. (Pubitemid 41136314)
38. Raykov, Z., Georgieva, P.B., Angelova, A., et al. (2009). Anticancer effects of an oncolytic parvovirus combined with nonconventional therapeutics on pancreatic carcinoma cell lines. Acta Virol. 53, 57-60.
39. Sandberg, L., Papareddy, P., Silver, J., et al. (2009). Replicationcompetent Ad11p vector (RCAd11p) efficiently transduces and replicates in hormone-refractory metastatic prostate cancer cells. Hum. Gene Ther. 20, 361-373.
40. Signorelli, P., and Ghidoni, R. (2005). Resveratrol as an anticancer nutrient: molecular basis, open questions and promises. J. Nutr. Biochem. 16, 449-466. (Pubitemid 41039220)
41. Small, E.J., Carducci, M.A., Burke, J.M., et al. (2006). A phase I trial of intravenous CG7870, a replication-selective, prostatespecific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol. Ther. 14, 107-117. (Pubitemid 43899483)
42. Surh, Y.J. (2003). Cancer chemoprevention with dietary phytochemicals. Nat. Rev. Cancer 3, 768-780.
43. Thomasset, S.C., Berry, D.P., Garcea, G., et al. (2007). Dietary polyphenolic phytochemicals-promising cancer chemopreventive agents in humans? A review of their clinical properties. Int. J. Cancer 120, 451-458. (Pubitemid 44969013)
44. Ulrich, S., Wolter, F., and Stein, J.M. (2005). Molecular mechanisms of the chemopreventive effects of resveratrol and its analogs in carcinogenesis. Mol. Nutr. Food Res. 49, 452-461. (Pubitemid 40780392)
45. Wang, Y., Hallden, G., Hill, R., et al. (2003). E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models. Nat. Biotechnol. 21, 1328-1335. (Pubitemid 37356618)
46. Yuan, J.P., Wang, J.H., and Liu, X. (2007). Metabolism of dietary soy isoflavones to equol by human intestinal microflora-implications for health. Mol. Nutr. Food Res. 51, 765-781. (Pubitemid 47173687)